Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5756316 | 0.91 | KDM4E (0.53) | KMT2AMAPTKDM4EMEN1SMN1; SMN2 | |
| SCHEMBL6479297 | 0.89 | POLB (0.46) | KMT2ACCR1MAPTKDM4EMEN1 | |
| SCHEMBL6478395 | 0.87 | MET (0.40) | KMT2ACCR1LMNAL3MBTL1KDM4E | |
| SCHEMBL5754686 | 0.83 | KDR (0.43) | CYP1A2LMNAMAPTKDM4E | |
| SCHEMBL5757017 | 0.81 | HDAC11 (0.43) | CYP1A2CYP2C19LMNAMAPTKDM4E | |
| SCHEMBL5756543 | 0.81 | HDAC11 (0.39) | MAPTL3MBTL1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL5756593 | 0.81 | KDM4E (0.49) | LMNAMAPTKDM4ERAB9AHTT | |
| SCHEMBL5757735 | 0.81 | HPGD (0.52) | KMT2ALMNAMAPTKDM4EMEN1 | |
| SCHEMBL5756899 | 0.80 | KMT2A (0.41) | KMT2AKDM4EMEN1SMN1; SMN2 | |
| SCHEMBL6490263 | 0.80 | HDAC11 (0.41) | KMT2AMAPTKDM4EMEN1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032869-A1 | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032869-A1 | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K9, MAP3K20, MAP3K19 | KMT2A 1158/4885CYP1A2 1895/4885CYP2C19 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.